Company Overview of EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company’s pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment ...
699 Boylston Street
Boston, MA 02116
Key Executives for EPIRUS Biopharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $428.1K
Chief Financial Officer, Senior Vice President and Treasurer
Total Annual Compensation: $292.7K
Chief Technical Officer and Senior Vice President
Total Annual Compensation: $294.2K
Compensation as of Fiscal Year 2014.
EPIRUS Biopharmaceuticals, Inc. Key Developments
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015
Nov 16 15
EPIRUS Biopharmaceuticals, Inc. announced the completion of manufacturing process lock and readiness for initiation of its pivotal global registration study. EPIRUS plans to initiate a global registration study for BOW015 (infliximab, reference biologic Remicadeii) in active Rheumatoid Arthritis (RA) patients in the United States, Europe and other markets in the first quarter of 2016. The company is on track for a harmonized global filing for marketing approval for BOW015 in 2017. EPIRUS continues to compile a comprehensive data package that will serve as the basis for the global filing. The forthcoming global registration study will build on positive data from EPIRUS' Phase 1 study in healthy volunteers conducted in the United Kingdom and Phase 3 study in active RA patients, which were presented at recent American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) meetings. These data reinforce the pharmacokinetic, safety and efficacy profile for BOW015, which further demonstrate the biosimilarity between BOW015 and Remicade. To date, between the clinical and market experience, nearly 750 patients have been treated with BOW015.
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 16 15
EPIRUS Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported revenue was $221,000 compared with Nil a year ago. Loss from operations was $14,042,000 against $13,929,000 a year ago. Net loss was $13,987,000 against $13,935,000 a year ago. Basic and diluted loss per share was $0.59 against $1.28 a year ago.
For the nine months, the company reported revenue was $291,000 compared with Nil a year ago. Loss from operations was $36,272,000 against $29,100,000 a year ago. Net loss was $36,794,000 against $31,445,000 a year ago. Basic and diluted loss per share was $1.66 against $8.15 a year ago.
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer
Nov 10 15
EPIRUS Biopharmaceuticals, Inc. announced that Vincent E. Aurentz has joined the Company as Chief Business Officer. Aurentz most recently served as the President of HemoShear Therapeutics, where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly,
Janssen R&D and Children's National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments.
Similar Private Companies By Industry
Recent Private Companies Transactions